Cardionat-Stada injection 100mg ml ampoule 5ml N10
Condition: New product
999 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Meldonius
Composition
Meldonium dihydrate * 100 mg per 1 ml, which corresponds to the content of meldonium 80.2 mg per 1 ml. Excipients: water d / and. * trimethylhydrazinium propionate dihydrate (in terms of dihydrate without adsorbed moisture).
Pharmacological effect
The drug, which improves metabolism and energy supply of tissues, is a synthetic analogue of gamma-butyrobetaine. Suppresses gamma-butyrobetaine hydroxinase. Reduces carnitine synthesis and transport of long-chain fatty acids through cell walls, prevents accumulation of activated forms of unoxidized fatty acids - acylcarnitine and acylcoenzyme A. Simultaneously, it activates glycolysis, which flows without additional consumption of oxygen. As a result of reducing the concentration of carnitine, gamma-butyrobetaine with vasodilating properties is intensively synthesized. The mechanism of action determines the diversity of the pharmacological effects of the drug: increased efficiency, reduction of symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective action. In the case of acute ischemic myocardial damage, it slows down the formation of a necrotic zone, shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of strokes. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes the redistribution of blood in favor of the ischemic area. Effective in the case of vascular and dystrophic pathology of the fundus. Also characteristic is the tonic effect on the central nervous system, the elimination of functional disorders of the somatic and autonomic nervous systems in patients with chronic alcoholism with withdrawal syndrome.
Pharmacokinetics
Data on the pharmacokinetics of the drug Cardionate is not provided.
Indications
- reduced performance; - increased physical activity; - The postoperative period to accelerate rehabilitation; - as part of combination therapy for CHD,chronic heart failure, cardialgia on the background of dyshormonal dystrophy of the myocardium; - complex therapy of abstinence alcohol syndrome; - acute and chronic forms of violation of cerebral circulation; - acute circulatory disorders in the retina, hemophthalmus and retinal hemorrhages of various etiologies; - Thrombosis of the central vein of the retina and its branches; - retinopathy of various etiologies (including diabetic and hypertensive) - only for parabulbar injection.
Contraindications
- increased intracranial pressure (in violation of the venous outflow and intracranial tumors); - pregnancy; - lactation period; - hypersensitivity to the drug.
Use during pregnancy and lactation
The drug is contraindicated for use during pregnancy and lactation (breastfeeding).
Dosage and administration
Increased mental and physical stress: in / in 1 g (10 ml) 1 time / day. The course of treatment is 10-14 days. If necessary, repeat the course in 2-3 weeks. In case of cardiovascular diseases (as part of complex therapy): in / in 0.5-1 g each (5-10 ml); The course of treatment is 10-14 days. Violation of cerebral circulation: acute phase - in / in 500 mg (5 ml) 1 time / day for 7-10 days, then go on ingestion. Chronic insufficiency of cerebral circulation: i / m 500 mg (5 ml) 1 time / day. The course of treatment is 10-14 days, then move to ingestion. Chronic alcoholism: in / in - 500 mg (5 ml), 2 times / day. The course of treatment is 7-10 days. Vascular pathology of the fundus and retinal dystrophy: retrobulbar and subconjunctival administered in 50 mg (0.5 ml solution for injection) for 10 days.
Side effects
Since the cardiovascular system: rarely - tachycardia, changes in blood pressure. Other: rarely - allergic reactions, dyspepsia, agitation.
Overdose
Data overdose drug Cardionat not provided.
Interaction with other drugs
Enhances the effect of coronarodilating agents and some antihypertensive drugs, cardiac glycosides. Can be combined with antianginal drugs, anticoagulants, antiplatelet agents, antiarrhythmic drugs, diuretics, bronchodilators. Due to the possible development of moderate tachycardia and hypotension, caution should be exercised in combination with nitroglycerin, nifedipine, alpha-blockers, antihypertensive drugs and peripheral vasodilators.
special instructions
Cardionate is not a first-line drug for acute coronary syndrome and its use is not urgently needed. Impact on the ability to drive vehicles and control mechanisms There is no data on the adverse effects of the Cardionate on the speed of psychomotor reactions.